J&J Gets $1.2 Billion Pass on Risperdal Fine
By EsqSocial Corporation 28/03/14
Two years ago, healthcare giant Johnson & Johnson was facing a $1.2 billion judgment after a jury determined J&J concealed the risks of its antipsychotic drug Risperdal while it aggressively and improperly marketed it off-label. At the time it was...
By: Searcy Denney Scarola Barnhart & Shipley